Overview

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).

Status:
Completed
Trial end date:
2018-09-20
Target enrollment:
Participant gender:
Summary
This is a multiple oral dose, open-label study to assess the safety, tolerability, and pharmacokinetics of SEP-363856 in Japanese subjects with schizophrenia.
Phase:
Phase 1
Details
Lead Sponsor:
Sumitomo Dainippon Pharma Co., Ltd.